241 related articles for article (PubMed ID: 35428435)
21. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L
J Womens Health (Larchmt); 2021 Apr; 30(4):474-491. PubMed ID: 33797277
[No Abstract] [Full Text] [Related]
22. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.
Kingsberg S; Shifren J; Wekselman K; Rodenberg C; Koochaki P; Derogatis L
J Sex Med; 2007 Jul; 4(4 Pt 1):1001-8. PubMed ID: 17627745
[TBL] [Abstract][Full Text] [Related]
24. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women.
Clayton AH; Goldstein I; Kim NN; Althof SE; Faubion SS; Faught BM; Parish SJ; Simon JA; Vignozzi L; Christiansen K; Davis SR; Freedman MA; Kingsberg SA; Kirana PS; Larkin L; McCabe M; Sadovsky R
Mayo Clin Proc; 2018 Apr; 93(4):467-487. PubMed ID: 29545008
[TBL] [Abstract][Full Text] [Related]
25. Lumping, Splitting, and Treating: Therapies Are Needed for Women With Overlapping Sexual Dysfunctions.
Pyke RE; Clayton AH
Sex Med Rev; 2019 Oct; 7(4):551-558. PubMed ID: 31204297
[TBL] [Abstract][Full Text] [Related]
26. Drugs in early clinical development for the treatment of female sexual dysfunction.
Belkin ZR; Krapf JM; Goldstein AT
Expert Opin Investig Drugs; 2015 Feb; 24(2):159-67. PubMed ID: 25376023
[TBL] [Abstract][Full Text] [Related]
27. Flibanserin for female sexual dysfunction.
Reviriego C
Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905
[TBL] [Abstract][Full Text] [Related]
28. Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians.
Cocchetti C; Ristori J; Mazzoli F; Vignozzi L; Maggi M; Fisher AD
Int J Impot Res; 2020 Nov; 33(7):703-709. PubMed ID: 33558671
[TBL] [Abstract][Full Text] [Related]
29. Comparison of androgens in women with hypoactive sexual desire disorder: those on combined oral contraceptives (COCs) vs. those not on COCs.
Warnock JK; Clayton A; Croft H; Segraves R; Biggs FC
J Sex Med; 2006 Sep; 3(5):878-882. PubMed ID: 16942531
[TBL] [Abstract][Full Text] [Related]
30. Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis.
Kornstein SG; Simon JA; Apfel SC; Yuan J; Barbour KA; Kissling R
J Womens Health (Larchmt); 2017 Nov; 26(11):1161-1168. PubMed ID: 28817365
[TBL] [Abstract][Full Text] [Related]
31. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
Kingsberg SA; Simon JA; Goldstein I
J Sex Med; 2008 Sep; 5 Suppl 4():182-93; quiz 193. PubMed ID: 18783534
[TBL] [Abstract][Full Text] [Related]
32. Advances in pharmacotherapy for treating female sexual dysfunction.
Nappi RE; Cucinella L
Expert Opin Pharmacother; 2015 Apr; 16(6):875-87. PubMed ID: 25732267
[TBL] [Abstract][Full Text] [Related]
33. Endocrine aspects of female sexual dysfunction.
Davis SR; Guay AT; Shifren JL; Mazer NA
J Sex Med; 2004 Jul; 1(1):82-6. PubMed ID: 16422987
[TBL] [Abstract][Full Text] [Related]
34. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD).
Clayton AH; Goldfischer ER; Goldstein I; Derogatis L; Lewis-D'Agostino DJ; Pyke R
J Sex Med; 2009 Mar; 6(3):730-8. PubMed ID: 19170868
[TBL] [Abstract][Full Text] [Related]
35. Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment.
Parish SJ; Hahn SR
Sex Med Rev; 2016 Apr; 4(2):103-120. PubMed ID: 27872021
[TBL] [Abstract][Full Text] [Related]
36. Flibanserin and Female Sexual Desire.
Fantasia HC
Nurs Womens Health; 2016; 20(3):309-14. PubMed ID: 27287358
[TBL] [Abstract][Full Text] [Related]
37. The yin and yang of GSM and low sexual desire.
Kingsberg SA; Adler B; Metropoulos J; Faubion SS
Climacteric; 2023 Aug; 26(4):323-328. PubMed ID: 37083058
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and Management of Hypoactive Sexual Desire Disorder.
Clayton AH; Kingsberg SA; Goldstein I
Sex Med; 2018 Jun; 6(2):59-74. PubMed ID: 29523488
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.
Jaspers L; Feys F; Bramer WM; Franco OH; Leusink P; Laan ET
JAMA Intern Med; 2016 Apr; 176(4):453-62. PubMed ID: 26927498
[TBL] [Abstract][Full Text] [Related]
40. Testosterone supplementation for hypoactive sexual desire disorder in women.
Woodis CB; McLendon AN; Muzyk AJ
Pharmacotherapy; 2012 Jan; 32(1):38-53. PubMed ID: 22392827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
